Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider
Objectives To systematically review the literature for assay methods that aim to evaluate type
I interferon (IFN-I) pathway activation and to harmonise-related terminology. Methods Three …
I interferon (IFN-I) pathway activation and to harmonise-related terminology. Methods Three …
2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice
J Rodríguez-Carrio, A Burska, PG Conaghan… - Annals of the …, 2023 - ard.bmj.com
Background Type I interferons (IFN-Is) play a role in a broad range of rheumatic and
musculoskeletal diseases (RMDs), and compelling evidence suggests that their …
musculoskeletal diseases (RMDs), and compelling evidence suggests that their …
Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing …
J Rodríguez-Carrio, A Burska, PG Conaghan… - RMD open, 2023 - rmdopen.bmj.com
Background Type I interferons (IFN-I) contribute to a broad range of rheumatic and
musculoskeletal diseases (RMDs). Compelling evidence suggests that the measurement of …
musculoskeletal diseases (RMDs). Compelling evidence suggests that the measurement of …
[PDF][PDF] Methods for type I interferon detection and their relevance for clinical utility and improved understanding of rheumatic diseases
L Lamot, I Niemietz, KL Brown - Clin Exp Rheumatol, 2019 - clinexprheumatol.org
Type I interferons (IFN) are a class of inducible and protective cytokines best known for
immune defence against viruses and intracellular bacteria. Inappropriate stimulation or …
immune defence against viruses and intracellular bacteria. Inappropriate stimulation or …
Assessment of type I interferon response in routine practice in France in 2022
A Nombel, AP Foray, L Garnier, C Lombard… - RMD open, 2023 - rmdopen.bmj.com
An European Alliance of Associations for Rheumatology task force recently recommended
specific points to consider for exploring type I interferon pathway in patients, highlighting the …
specific points to consider for exploring type I interferon pathway in patients, highlighting the …
Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases
JC Hall, L Casciola-Rosen, AE Berger… - Proceedings of the …, 2012 - National Acad Sciences
Elucidating the molecular pathways active in pathologic tissues has important implications
for defining disease subsets, selecting therapy, and monitoring disease activity. The …
for defining disease subsets, selecting therapy, and monitoring disease activity. The …
The type I IFN signature as a biomarker of preclinical rheumatoid arthritis
J Lübbers, M Brink, LA van de Stadt… - Annals of the …, 2013 - ard.bmj.com
Objectives To validate the presence and demonstrate the clinical value of the type I
interferon (IFN)-signature during arthritis development. Method In 115 seropositive arthralgia …
interferon (IFN)-signature during arthritis development. Method In 115 seropositive arthralgia …
Interferon β is associated with type 1 interferon-inducible gene expression in dermatomyositis
AP Liao, M Salajegheh, R Nazareno… - Annals of the …, 2011 - ard.bmj.com
Objectives To determine whether type 1 interferon (IFN) proteins in blood are associated
with downstream type 1 IFN-inducible gene expression in blood from patients with myositis …
with downstream type 1 IFN-inducible gene expression in blood from patients with myositis …
Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway
BW Higgs, Z Liu, B White, W Zhu, WI White… - Annals of the …, 2011 - ard.bmj.com
Objective To characterise activation of the type I interferon (IFN) pathway in patients with
systemic lupus erythematosus (SLE), dermatomyositis (DM), polymyositis (PM), rheumatoid …
systemic lupus erythematosus (SLE), dermatomyositis (DM), polymyositis (PM), rheumatoid …
[HTML][HTML] Heterogeneity of the type I interferon signature in rheumatoid arthritis: a potential limitation for its use as a clinical biomarker
J Rodríguez-Carrio, M Alperi-López, P López… - Frontiers in …, 2018 - frontiersin.org
Introduction An increased expression of interferon (IFN)-responding genes (IRGs), the so-
called IFN signature, has been reported in rheumatoid arthritis (RA). However, some …
called IFN signature, has been reported in rheumatoid arthritis (RA). However, some …